Perspective: Emerging Challenges in the Treatment of Influenza and Parainfluenza in Transplant Patients

Table 1

Similarities and differences between IFV and PIV infections in the immunocompromised host.

	Significant morbidity and mortality	RNA virus	Respiratory receptor	Peak incidence	Vaccination during posttransplant period	Antivirals	Antiviral resistance
Influenza	Yes	Yes	Sialic acids	Seasonal	Yes (reduced efficacy)	Yes (unproven efficacy)	Yes
Parainfluenza	Yes	Yes	Sialic acids	Perennial	None licensed	No	N/A